{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IVC+Papillary+Thyroid+Cancer",
    "query": {
      "condition": "Stage IVC Papillary Thyroid Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:32:15.073Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00085293",
      "title": "Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Thyroid Cancer",
        "Stage IVA Follicular Thyroid Cancer",
        "Stage IVA Papillary Thyroid Cancer",
        "Stage IVB Follicular Thyroid Cancer",
        "Stage IVB Papillary Thyroid Cancer",
        "Stage IVC Follicular Thyroid Cancer",
        "Stage IVC Papillary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Iodine I 131",
          "type": "RADIATION"
        },
        {
          "name": "Recombinant thyrotropin alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludeoxyglucose F 18",
          "type": "RADIATION"
        },
        {
          "name": "Positron emission tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2004-05",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Columbus, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085293"
    },
    {
      "nct_id": "NCT01413113",
      "title": "Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Thyroid Cancer",
        "Stage IVA Follicular Thyroid Cancer",
        "Stage IVA Papillary Thyroid Cancer",
        "Stage IVB Follicular Thyroid Cancer",
        "Stage IVB Papillary Thyroid Cancer",
        "Stage IVC Follicular Thyroid Cancer",
        "Stage IVC Papillary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "pazopanib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "iodine I 131",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2011-12",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-11-05",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01413113"
    },
    {
      "nct_id": "NCT02152995",
      "title": "Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Carcinoma",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Iodine I 124",
          "type": "OTHER"
        },
        {
          "name": "Iodine I-131",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacodynamic Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2014-08-14",
      "completion_date": "2027-02-05",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02152995"
    },
    {
      "nct_id": "NCT00519896",
      "title": "Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Thyroid Cancer",
        "Stage IVA Follicular Thyroid Cancer",
        "Stage IVA Papillary Thyroid Cancer",
        "Stage IVB Follicular Thyroid Cancer",
        "Stage IVB Papillary Thyroid Cancer",
        "Stage IVC Follicular Thyroid Cancer",
        "Stage IVC Papillary Thyroid Cancer",
        "Thyroid Gland Medullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2007-07",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-04-25",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00519896"
    },
    {
      "nct_id": "NCT02973997",
      "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Columnar Cell Variant Thyroid Gland Papillary Carcinoma",
        "Follicular Variant Thyroid Gland Papillary Carcinoma",
        "Metastatic Thyroid Gland Follicular Carcinoma",
        "Metastatic Thyroid Gland Papillary Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Follicular Carcinoma",
        "Recurrent Thyroid Gland Papillary Carcinoma",
        "Stage III Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage III Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7",
        "Tall Cell Variant Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Hurthle Cell Carcinoma",
        "Unresectable Differentiated Thyroid Gland Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2018-02-07",
      "completion_date": "2023-10-08",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 7,
      "location_summary": "Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973997"
    },
    {
      "nct_id": "NCT01811212",
      "title": "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Stage I Thyroid Gland Follicular Carcinoma",
        "Stage I Thyroid Gland Papillary Carcinoma",
        "Stage II Thyroid Gland Follicular Carcinoma",
        "Stage II Thyroid Gland Papillary Carcinoma",
        "Stage III Thyroid Gland Follicular Carcinoma",
        "Stage III Thyroid Gland Papillary Carcinoma",
        "Stage IVA Thyroid Gland Follicular Carcinoma",
        "Stage IVA Thyroid Gland Papillary Carcinoma",
        "Stage IVB Thyroid Gland Follicular Carcinoma",
        "Stage IVB Thyroid Gland Papillary Carcinoma",
        "Stage IVC Thyroid Gland Follicular Carcinoma",
        "Stage IVC Thyroid Gland Papillary Carcinoma",
        "Tall Cell Variant Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Oncocytic Follicular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-05-08",
      "completion_date": "2017-10-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Jacksonville, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01811212"
    },
    {
      "nct_id": "NCT00068497",
      "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Insular Thyroid Cancer",
        "Metastatic Parathyroid Cancer",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Parathyroid Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Thyroid Cancer",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Stage III Follicular Thyroid Cancer",
        "Stage III Papillary Thyroid Cancer",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IVA Basal Cell Carcinoma of the Lip",
        "Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Follicular Thyroid Cancer",
        "Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Lymphoepithelioma of the Oropharynx",
        "Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IVA Papillary Thyroid Cancer",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVA Squamous Cell Carcinoma of the Larynx",
        "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Verrucous Carcinoma of the Larynx",
        "Stage IVA Verrucous Carcinoma of the Oral Cavity",
        "Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IVB Basal Cell Carcinoma of the Lip",
        "Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Follicular Thyroid Cancer",
        "Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Lymphoepithelioma of the Oropharynx",
        "Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IVB Papillary Thyroid Cancer",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVB Squamous Cell Carcinoma of the Larynx",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Verrucous Carcinoma of the Larynx",
        "Stage IVB Verrucous Carcinoma of the Oral Cavity",
        "Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IVC Basal Cell Carcinoma of the Lip",
        "Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Follicular Thyroid Cancer",
        "Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Lymphoepithelioma of the Oropharynx",
        "Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IVC Papillary Thyroid Cancer",
        "Stage IVC Salivary Gland Cancer",
        "Stage IVC Squamous Cell Carcinoma of the Larynx",
        "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVC Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Verrucous Carcinoma of the Larynx",
        "Stage IVC Verrucous Carcinoma of the Oral Cavity",
        "Thryoid Gland Nonmedullary Carcinoma",
        "Thyroid Gland Medullary Carcinoma",
        "Tongue Cancer",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2003-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-14",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068497"
    },
    {
      "nct_id": "NCT00381641",
      "title": "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Carcinoma",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage III Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7",
        "Thyroid Gland Oncocytic Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2006-08-29",
      "completion_date": "2024-12-10",
      "has_results": true,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 17,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 13 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381641"
    },
    {
      "nct_id": "NCT02393690",
      "title": "Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Iodine I-131",
          "type": "RADIATION"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2015-05-04",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Newport Beach, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02393690"
    },
    {
      "nct_id": "NCT00416949",
      "title": "Iodine I 131 in Treating Patients With Thyroid Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Patient-specific dosimetry",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 9,
      "start_date": "2006-04",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2018-07-18",
      "last_synced_at": "2026-05-21T22:32:15.073Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00416949"
    }
  ]
}